native glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 physiology in obesity and

pylori antibiotics, but which substances play the main role and whether multiple substances have synergistic effects need further identification and experimental verification

Gastrointestinal discomfort Occasionally, mild bloating or nausea may occur

Although most GLP-1 therapies are injectable, oral formulations are being developed to improve patient convenience

Tirzepatide: Stands out for its dual agonism (GLP-1 and GIP receptors), resulting in substantial weight loss in addition to glycemic control

All female life stages will receive hormonal support and a balancing of estrogen levels appropriate to age and condition as well as fighting the effects of plastics in the environment which has been found to affect a womans estrogen levels